Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Fulveryze Fulvestrant Injection 250mg/5ml
Fulveryze Fulvestrant Injection 250mg/5ml is a hormonal therapy used in the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women. Fulvestrant is an estrogen receptor antagonist that works by blocking and degrading estrogen receptors, which slows the growth of estrogen-sensitive breast cancer cells.
Uses of Fulveryze Fulvestrant Injection 250mg/5ml
Treating hormone receptor-positive metastatic breast cancer in postmenopausal women
Used in combination with other therapies for advanced breast cancer
Managing cancer progression after failure of other anti-estrogen therapies
Benefits of Fulveryze Fulvestrant Injection 250mg/5ml
Targeted Therapy: Specifically targets estrogen receptors, providing a focused treatment approach.
Effective in Advanced Cancer: Proven efficacy in managing metastatic breast cancer.
Combination Therapy: Can be used with other treatments for enhanced therapeutic effect.
Well-Tolerated: Generally well-tolerated with manageable side effects.
Mechanism of Action of Fulveryze Fulvestrant Injection 250mg/5ml
Fulvestrant works by binding to estrogen receptors on breast cancer cells, leading to receptor degradation and downregulation. This process blocks the effects of estrogen on the cancer cells, inhibiting their growth and proliferation. By reducing the number of estrogen receptors, Fulveryze Fulvestrant Injection effectively slows the progression of hormone receptor-positive breast cancer. This targeted mechanism makes it a valuable option for treating advanced breast cancer in postmenopausal women.